N Engl J Med 2019 Oct 31
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Related Questions
New answer by Medical Oncologist at Roswell Park Cancer Center (April 2, 2021)
In general, there is no "optimal" intensive salvage regimen for relapsed/refractory AML failing prior 7+3 and HIDAC consolidation. Prior comparisons of cytotoxic regimens have...